ADPA-2M4CD8 is under clinical development by Adaptimmune Therapeutics and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect ADPA-2M4CD8’s likelihood of approval (LoA) and phase transition for Endometrial Cancer took place on 02 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their ADPA-2M4CD8 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
ADP-A2M4CD8 is under development for the treatment of solid tumors including platinum-resistant ovarian cancer, urothelial carcinoma, endometrial cancer, esophageal cancer, melanoma, esophagogastric junction (EGJ) cancer, gastric cancer, non-small cell lung carcinoma (NSCLC), peritoneal cancer, fallopian tube cancer and head and neck cancer. The therapeutic candidate comprises of CD8 alpha co-receptor alongside the autologous genetically modified engineered TCR that targets MAGE-A4. It is a next-generation of ADP-A2M4 which is administered by parenteral route. It is developed based on SPEAR T-cell platform.
It was under development for synovial sarcoma, myxoid, round cell liposarcoma and bladder cancer.
Adaptimmune Therapeutics overview
Adaptimmune Therapeutics (Adaptimmune), formerly Adaptimmune Therapeutics is a clinical stage bio pharmaceutical company that develops innovative T-cell therapy products for the treatment of cancer. It harnesses the proprietary SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform that engineers the T-cells to identify and exterminate cancer, including solid tumors. The company’s pipeline products include NY-ESO TCR for synovial sarcoma and multiple myeloma; MAGE A4 TCR for multiple solid tumors; AFP TCR for hepatocellular cancer; and MAGE-A10 TCR for bladder, melanoma, and head and neck cancer. The company has presence in the US and the UK. Adaptimmune is headquartered in Abingdon, Oxfordshire, the UK.
Quick View ADPA-2M4CD8 LOA Data
|Highest Development Stage|